Leukotriene B4 biosynthetic pathway (LTB4 biosynthetic pathway)

The Leukotriene B4 (LTB4) production pathway, a specialized branch of arachidonate metabolism, is a critical enzymatic cascade responsible for generating potent lipid mediators of the inflammatory response [1, 2]. The process begins with the release of arachidonic acid from cell membranes by phospholipase A2, which is then converted into the unstable intermediate leukotriene A4 (LTA4) by the enzyme 5-lipoxygenase (5-LOX) in conjunction with the 5-lipoxygenase-activating protein (FLAP) [1, 6]. LTA4 is subsequently hydrolyzed by leukotriene A4 hydrolase (LTA4H) to produce LTB4, a powerful chemoattractant that recruits and activates neutrophils, monocytes, and T cells to sites of injury or infection [1, 10]. Dysregulation of this pathway is a hallmark of various chronic inflammatory and autoimmune conditions, including asthma, chronic obstructive pulmonary disease (COPD), and cardiovascular disorders [5, 8]. Therapeutic strategies focus on inhibiting key enzymes in the cascade, such as 5-LOX (e.g., zileuton) or LTA4H (e.g., acebilustat), to dampen LTB4-mediated inflammation [3, 4]. However, pharmacological modulation requires careful monitoring for potential hepatotoxicity and the risk of "eicosanoid shunting," where arachidonic acid is diverted to other pro-inflammatory pathways [5, 10].

Other names

Leukotriene B4 productionArachidonate metabolism5-Lipoxygenase pathwayLTB4 synthesis pathwayArachidonic acid cascade

Inhibition of enzymes within the arachidonic acid cascade, specifically 5-lipoxygenase (5-LOX), 5-lipoxygenase-activating protein (FLAP), or leukotriene A4 hydrolase (LTA4H), to prevent the synthesis of the pro-inflammatory mediator leukotriene B4 [1, 2].